LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • F8270

    Furosemide

    Loop diuretic; NKCC symporter inhibitor, CFTR C...

    ≥97%
  • A9601

    AZD-5363

    AKT inhibitor, potential ROCK, p70S6K, PKA, MKK...

    ≥99%, ≥99%ee
  • P005095

    N-Debenzoylpaclitaxel

    Paclitaxel derivative

    ≥95%
  • M4454

    MLN-4924

    Nedd8-activating enzyme inhibitor.

    ≥99%
  • N5550

    Nomilin

    Triterpene found in species of Citrus; HIV-1 pr...

    ≥98%
  • C0148

    Calcitonin, human

    Endogenous neuropeptide hormone, lowers extrace...

    ≥95%
  • E5219

    Endothelin-1, human

    Endogenous peptide involved in vascular contrac...

    ≥95%
  • T0081

    Taurine

    Endogenous sulfonic acid involved in Ca2+ signa...

    ≥99%
  • V1668

    Vemurafenib

    B-Raf inhibitor.

    ≥98%
  • O1176

    n-Octyl Caffeate

    Caffeic acid derivative.

    ≥98%
  • I7559

    Isoliquiritigenin, natural

    Chalcone; SIRT activator, GABA-A positive modul...

    ≥99%
  • T176503

    Temsirolimus

    Analog of rapamycin.

    ≥98%
  • D3210

    Diclofenac free acid

    Somewhat selective in inhibiting COX-2 over COX...

    ≥99%
  • H9718

    2-Hydroxyflutamide

    Non-steroid; AR antagonist.

    ≥98%
  • X4400

    XL-228

    Abl (T315I) inhibitor.

    ≥98%
  • D3322

    Diflunisal

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • E9819

    Ezetimibe

    NPC1L1 inhibitor.

    ≥99%
  • L0400

    LB-100

    PP2A inhibitor.

    ≥98%
  • M578522

    Monascin

    Fungal pigment found in red yeast rice

    ≥98%
  • C1613

    Cediranib

    VEGFR inhibitor.

    ≥98%